Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malignant mesothelioma. The study demonstrated no clinically meanin...

Descripción completa

Detalles Bibliográficos
Autores principales: Baverel, Paul, Roskos, Lorin, Tatipalli, Manasa, Lee, Nancy, Stockman, Paul, Taboada, Maria, Vicini, Paolo, Horgan, Kevin, Narwal, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742946/
https://www.ncbi.nlm.nih.gov/pubmed/30883000
http://dx.doi.org/10.1111/cts.12633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742946/
https://www.ncbi.nlm.nih.gov/pubmed/30883000
http://dx.doi.org/10.1111/cts.12633

Ejemplares similares